| Detailed information |
|---|
| CancerLivER ID | 2115 |
| Biomarker | Galectin-1 |
| Biomarker Name/Symbol (given in Publication) | Galectin-1 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer |
| Experimental Condition | HCC patients treated with sorafenib vs HCC untreated patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | High pretreatment galectin-1 levels remained an independent predictor of shorter progression-free survival and overall survival |
| Level of significance | p < 0.01 |
| Source | Serum |
| PMID | 25850433 |
| Type of Biomarker | Predictive |
| Pathway | AKT/mTOR/HIF-1 signaling pathway |
| Cohort | 91 HCC patients who received sorafenib-based treatment as the first-line therapy for advanced HCC; The HCC HuH-7 cell line was obtained from the Health Science Research Resources Bank (JCRB0403, Osaka, Japan). The sorafenib-resistant HCC cell line, HuH-7R, was established by long-term exposure of ce |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | sorafenib-resistant HCC cell line, HuH-7R, was established by long-term exposure of cells to sorafenib; 91 HCC patients who received sorafenib-based treatment as the first-line therapy for advanced HCC ; xenograft tumors formed from HuH-7 or HuH-7R tumors (n = 6 each)[BALB/c nude mice liver cancer] |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |